{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:30:19Z","timestamp":1788219019259,"version":"build-2803163510"},"reference-count":41,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of ketamine or ketorolac compared to opioids in painful vaso-occlusive crisis (VOC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data resources:<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) criteria and used Embase, MEDLINE, and Cochrane Central to obtain data that evaluated the efficacy and safety of ketamine or ketorolac compared to opioids in acute painful VOC in July of 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>\n                      The primary endpoints were meaningful reduction of pain on pain scales, reduction in opioid requirements, and the incidence of adverse effects reported in the studies. A\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -value of &lt;0.05 was considered statistically significant, and heterogeneity among the studies was reported as the I\n                      <jats:sup>2<\/jats:sup>\n                      value.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>\n                      Eight randomized controlled trials were included. Ketorolac showed a statistically significant pain reduction compared to opioids (standard mean difference [SMD]: 0.58 [95% CI: 0.31-0.85,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001]), whereas ketamine showed no statistically significant difference in pain reduction (MD: \u22120.17 [95% CI: \u22120.53 to 0.18,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.34]). A statistically significant reduction in opioid requirements was demonstrated in both intervention groups (MD: 3.23 [95% CI: \u22124.40 to \u22122.06,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001]). Regarding safety, ketorolac showed a lower risk of adverse effects compared to opioids (risk ratio [RR]: 0.54 [95% CI: 0.36-0.79,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0019]), while ketamine demonstrated a higher risk of adverse effects (RR: 9.90 [95% CI: 4.30-22.82,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice:<\/jats:title>\n                    <jats:p>Ketamine or ketorolac demonstrated effective reduction in pain and opioid requirements, with ketorolac showing a greater pain relief and a favorable safety profile compared to ketamine. These findings demonstrate their use as either nonopioid analgesics or opioid-sparing agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Ketamine or ketorolac may not only reduce opioid requirements but may also serve as nonopioid treatment options, supporting safer and individualized pain-management strategies in painful VOC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251380939","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:03:33Z","timestamp":1762247013000},"page":"555-566","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["The Efficacy and Safety of Ketamine or Ketorolac Compared to Opioids in Painful Vaso-Occlusive Crisis: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2590-6054","authenticated-orcid":false,"given":"May M.","family":"Shehata","sequence":"first","affiliation":[{"name":"The University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0321-5608","authenticated-orcid":false,"given":"Justin P.","family":"Reinert","sequence":"additional","affiliation":[{"name":"The University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Centers for Disease Control. Data and statistics on sickle cell disease. Published 2024. Accessed July 16 2025. https:\/\/www.cdc.gov\/sickle-cell\/data\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2025.103512"},{"key":"e_1_3_3_4_2","unstructured":"Centers for Disease Control. Complications of SCD: pain. Published 2024. Accessed July 16 2025. https:\/\/www.cdc.gov\/sickle-cell\/complications\/pain.html"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13430"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001851"},{"key":"e_1_3_3_7_2","unstructured":"Ketorolac Tromethamine (Toradol) [Package insert]. Roche Laboratories Inc; 2013. Accessed August 27 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019645s019lbl.pdf"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X112471"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3623-6"},{"key":"e_1_3_3_10_2","unstructured":"Ketamine Hydrochloride (Ketalar) [Package insert]. Pfizer Corporation Hong Kong; 2024. Accessed July 16 2025. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=14017"},{"key":"e_1_3_3_11_2","unstructured":"National Heart Lung and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report 2014. National Heart Lung and Blood Institute; 2014. Accessed July 16 2025. https:\/\/www.nhlbi.nih.gov\/health-topics\/evidence-based-management-sickle-cell-disease"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20403"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.442.442"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\/14898"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-025-3351-0"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/acem.14382"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.5812\/ircmj.83614"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1515\/sjpain-2017-0140"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006565-199906000-00004"},{"issue":"4","key":"e_1_3_3_21_2","first-page":"239","article-title":"Ketorolac versus meperidine in vaso-occlusive crisis: a study of safety and efficacy","volume":"3","author":"Grisham J","year":"1996","unstructured":"Grisham J, Vichinsky E. Ketorolac versus meperidine in vaso-occlusive crisis: a study of safety and efficacy. IJPHO. 1996;3(4):239-247.","journal-title":"IJPHO"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830460108"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0196-0644(05)82929-4"},{"key":"e_1_3_3_24_2","unstructured":"Meta-Mar v4.0.2: a next-generation meta-analysis platform. Accessed July 18 2025. https:\/\/www.meta-mar.com\/"},{"key":"e_1_3_3_25_2","unstructured":"Meta-converter for the SD of change. Accessed July 18 2025. https:\/\/meta-converter.com\/conversions\/mean-sd-change"},{"key":"e_1_3_3_26_2","unstructured":"National Center for Biotechnology Information. Final Values and Change From Baseline Calculations. National Library of Medicine. Accessed July 18 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK588008\/"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000003529"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(96)70238-X"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001952"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2021.03.008"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2023.11.012"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2017.197"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/pan.12172"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002290"},{"key":"e_1_3_3_36_2","unstructured":"Department of Justice Drug Enforcement Administration. Drug fact sheet: ketamine. Published 2020. Accessed July 21 2025. https:\/\/www.dea.gov\/sites\/default\/files\/2020-06\/Ketamine-2020.pdf"},{"key":"e_1_3_3_37_2","unstructured":"Orhurhu VJ Vashisht R Claus LE et al. Ketamine Toxicity. StatPearls Publishing; 2025. Accessed July 21 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541087\/"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21763"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.155.4.496"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.8"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1590\/2175-8239-JBN-2018-0107"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251380939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251380939","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251380939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:21:43Z","timestamp":1778840503000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251380939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10600280251380939"],"URL":"https:\/\/doi.org\/10.1177\/10600280251380939","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}